Page 27 - Report From News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Doctor speaks with a patient in the intensive care unit. Ever since the coronavirus became a widespread global pandemic, medical researchers have sought to understand how the virus impacts other medical ailments, especially neurological ones. In early 2020, New York’s Mount Sinai Hospital reported that five younger patients stricken with COVID-19 experienced strokes after their diagnosis. This worrying report led researchers to fear that the virus could lead to an increase in stroke risk even in patients with no history of vascular disease, like high blood pressure, diabetes or smoking. ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and ... Amarin Corporation plcApril 22, 2021 GMT VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication 1,2, VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Medicines and ...

Message : Required fields Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce ... Amarin Corporation plcMarch 17, 2021 GMT 28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke obser...

Share: 28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Awa...